DCM
ENTA icon

Delpha Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Delpha Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-788
Closed -$46K – 444
2017
Q4 		$46K Buy
+788
New +$39.5K 0.05% 342

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Delpha Capital Management's ENTA Position: Q1 2018 in Review

Delpha Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2018, closing a stake of 788 shares — an estimated $46K sold.

Delpha Capital Management first reported a position in ENTA in Q4 2017 and held it in 1 quarter. The position peaked at $46K in Q4 2017. 181 funds tracked by Wall St. Rank hold ENTA as of Q1 2018.

  • Delpha Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 788 Enanta Pharmaceuticals shares in Q1 2018, an estimated $46K.
  • Delpha Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Enanta Pharmaceuticals position peaked at $46K in Q4 2017.
  • 181 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.